Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas.
CIMP status
MSI-like signature
colorectal carcinoma
gene signature
prognosis
promoter methylation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Jan 2021
05 Jan 2021
Historique:
received:
23
12
2020
accepted:
30
12
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
21
1
2021
Statut:
epublish
Résumé
Epigenetics is involved in tumor progression and drug resistance in human colorectal carcinoma (CRC). This study addressed the hypothesis that the DNA methylation profiling may predict the clinical behavior of metastatic CRCs (mCRCs). The global methylation profile of two human mCRC subgroups with significantly different outcome was analyzed and compared with gene expression and methylation data from The Cancer Genome Atlas COlon ADenocarcinoma (TCGA COAD) and the NCBI GENE expression Omnibus repository (GEO) GSE48684 mCRCs datasets to identify a prognostic signature of functionally methylated genes. A novel epigenetic signature of eight hypermethylated genes was characterized that was able to identify mCRCs with poor prognosis, which had a CpG-island methylator phenotype (CIMP)-high and microsatellite instability (MSI)-like phenotype. Interestingly, methylation events were enriched in genes located on the q-arm of chromosomes 13 and 20, two chromosomal regions with gain/loss alterations associated with adenoma-to-carcinoma progression. Finally, the expression of the eight-genes signature and MSI-enriching genes was confirmed in oxaliplatin- and irinotecan-resistant CRC cell lines. These data reveal that the hypermethylation of specific genes may provide prognostic information that is able to identify a subgroup of mCRCs with poor prognosis.
Identifiants
pubmed: 33466447
pii: cancers13010158
doi: 10.3390/cancers13010158
pmc: PMC7796477
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Med Sci (Basel). 2018 Apr 13;6(2):
pubmed: 29652830
Cancer Res. 2006 Oct 15;66(20):9804-8
pubmed: 17047040
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Trends Pharmacol Sci. 2010 Nov;31(11):536-46
pubmed: 20846732
Cancer Res. 2008 Nov 15;68(22):9532-40
pubmed: 19010930
Gastroenterology. 2002 Oct;123(4):1109-19
pubmed: 12360473
Nature. 2008 Oct 23;455(7216):1069-75
pubmed: 18948947
Pharmacotherapy. 2014 May;34(5):495-505
pubmed: 24619798
Adv Biomed Res. 2018 Feb 16;7:28
pubmed: 29531926
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375
pubmed: 30886395
Science. 2018 Sep 28;361(6409):1336-1340
pubmed: 30262495
Surg Oncol Clin N Am. 2018 Apr;27(2):377-399
pubmed: 29496096
J Pathol. 2012 Dec;228(4):586-95
pubmed: 22926706
Epigenetics. 2019 Dec;14(12):1164-1176
pubmed: 31282279
World J Clin Cases. 2018 Dec 6;6(15):869-881
pubmed: 30568941
Curr Treat Options Oncol. 2015 Nov;16(11):52
pubmed: 26374340
Oncology. 2019;96(3):156-163
pubmed: 30540994
Cell. 2012 Jul 6;150(1):12-27
pubmed: 22770212
Transl Oncol. 2018 Oct;11(5):1188-1201
pubmed: 30071442
Arch Pharm Res. 2019 Feb;42(2):159-170
pubmed: 30806885
Sci Rep. 2015 Nov 25;5:16923
pubmed: 26603754
Indian J Surg Oncol. 2017 Dec;8(4):580-590
pubmed: 29203992
Oncologist. 2020 Jun;25(6):481-487
pubmed: 31967692
Epigenomics. 2019 May 1;11(6):587-604
pubmed: 31066579
Clin Adv Hematol Oncol. 2018 Nov;16(11):735-745
pubmed: 30543589
Cancer Res. 2018 Feb 1;78(3):631-644
pubmed: 29229600
Int J Mol Sci. 2017 Jan 19;18(1):
pubmed: 28106826
Genome Res. 2012 Feb;22(2):271-82
pubmed: 21659424
Nat Rev Genet. 2012 Oct;13(10):679-92
pubmed: 22945394
J Clin Invest. 2014 Jan;124(1):14-6
pubmed: 24382384
Clin Epigenetics. 2016 Mar 02;8:25
pubmed: 26941852
Gastroenterology. 2015 Oct;149(5):1204-1225.e12
pubmed: 26216839
Gastrointest Tumors. 2014 May;1(4):209-20
pubmed: 26676107
Oncologist. 2018 Jan;23(1):25-34
pubmed: 29021377
Nat Rev Genet. 2016 Sep 15;17(10):630-41
pubmed: 27629931
Cancer Discov. 2015 Jan;5(1):16-8
pubmed: 25583798
Br J Cancer. 2006 Apr 24;94(8):1087-92
pubmed: 16495912
BMC Syst Biol. 2010 Apr 27;4:51
pubmed: 20420713
Cells. 2019 Jun 03;8(6):
pubmed: 31163702
Leuk Res. 2018 Oct;73:95-102
pubmed: 30257227
Lancet Oncol. 2017 Sep;18(9):1159-1171
pubmed: 28781171
Cell Commun Signal. 2019 Jul 22;17(1):79
pubmed: 31331345
Biomed Res Int. 2019 Mar 17;2019:6763596
pubmed: 31008109
World J Surg Oncol. 2019 Oct 21;17(1):169
pubmed: 31639018
Trends Cancer. 2017 Oct;3(10):698-712
pubmed: 28958388
Curr Treat Options Oncol. 2015 Jul;16(7):30
pubmed: 26031544
Int J Cancer. 2020 Jun 1;146(11):3065-3076
pubmed: 32017074
Cancer Cell Int. 2015 Oct 13;15:98
pubmed: 26464562
Epigenomics. 2016 May;8(5):685-703
pubmed: 27102979
Mol Oncol. 2013 Jun;7(3):669-79
pubmed: 23522960
Nat Rev Clin Oncol. 2010 Mar;7(3):153-62
pubmed: 20142816